MedTrace Logo

Treatments for Psychogenic Nonepileptic Seizures (NES)

NCT00159965 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2014-11-20

Study results available
· View outcomes & findings →

Summary

The investigators propose that treatment of the comorbid disorders (depression, anxiety, and impulsivity) with sertraline in patients with lone psychogenic nonepileptic seizures (NES), will result in a decreased number of NES. The purpose of this study is to provide pilot testing and data to inform the future randomized controlled trial based on the hypothesis.

Conditions

  • Convulsion, Non-Epileptic
  • Conversion Disorder
  • Depression
  • Stress Disorders, Post-Traumatic

Interventions

DRUG

sertraline

flexible dose sertraline

DRUG

placebo

flexible dose placebo

Sponsors & Collaborators

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • Rhode Island Hospital

    lead OTHER

Principal Investigators

  • W. Curt LaFrance, Jr., MD, MPH · Rhode Island Hospital/Brown Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2008-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00159965 on ClinicalTrials.gov